As of December 31, 2024, Immunovant’s (IMVT) cash and cash equivalents totaled $374.7M. “We are energized by the progress of our IMVT-1402 development plans, with six INDs now cleared and all clinical studies to be conducted using standard YpsoMate autoinjector technology and our planned commercial formulation,” said Pete Salzmann, CEO. “We continue to expect to share the top line results from our batoclimab pivotal study in MG and period one results from our study in CIDP by the end of this quarter, and anticipate these results being used to further optimize our development plans for our potentially best-in-class lead asset, IMVT-1402.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Insider Trading: Immunovant’s (IMVT) Major Investor Boosts Stake by $337M
- Immunovant price target lowered to $45 from $48 at BofA
- Immunovant Progresses in Autoimmune Therapy Development
- Immunovant Raises $450 Million Through Share Purchase Agreement
- Immunovant to sell 22.5M shares at $25.00 in private placement